Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

NCT01500551 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

302

Enrollment

INDUSTRY

Sponsor class

Conditions

Juvenile Idiopathic Arthritis

Interventions

DRUG: Tofacitinib
DRUG: Tofacitinib

Sponsor

Pfizer